Drug intelligence / Profile preview

nadroparin

Development stage
Phase 4
Lead developer
Sanofi
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous
01

Overview

Nadroparin is a low molecular weight heparin (LMWH) anticoagulant derived from porcine sources. It is used for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism, unstable angina, and non-Q-wave myocardial infarction. Nadroparin is also indicated to prevent clotting during hemodialysis and in patients undergoing general or orthopedic surgery at risk of thromboembolism. Its mechanism of action involves high-affinity binding to antithrombin III (ATIII), which accelerates the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin), thereby inhibiting the coagulation cascade. Additional antithrombotic effects include stimulation of tissue factor pathway inhibitor release and activation of fibrinolysis via tissue plasminogen activator from endothelial cells. Developed and manufactured by Sanofi.

Brand names
Fraxiparine
Other names
nadroparin calcium
02

Targets

ATIII (Antithrombin III)F10 (Factor Xa)F2 (Thrombin)

Beyond the preview

Go deeper on nadroparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nadroparin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call